Short Report

Early and massive testing saves lives: COVID-19 related infections and deaths in the United States during March of 2020

James B. Hittner¹, Folorunso O. Fasina^{2*}, Almira L. Hoogesteijn³, Renata Piccinini⁴, Prakasha Kempaiah⁵, Stephen D. Smith⁶, and Ariel L. Rivas⁷

¹Department of Psychology, College of Charleston, Charleston, South Carolina, United States of America; ²Food and Agriculture Organization, Dar es Salam, Tanzania; ³Human Ecology, Centro de Investigación y de Estudios Avanzados (CINVESTAV), Mérida, México; ⁴Department of Veterinary Medicine, University of Milan, Milan, Italy; ⁵Loyola University Medical Center, Chicago, Illinois, United States of America; ⁶Institute for Resource Information Science, College of Agriculture, Cornell University, Ithaca, United States of America; ⁷Center for Global Health, Department of Internal Medicine, Medical School, University of New Mexico, Albuquerque, New Mexico, United States of America

* **Correspondence to:** Folorunso O. Fasina, FAO ECTAD Tanzania & Department of Veterinary Tropical Diseases, University of Pretoria, South Africa; Email: Folorunso.fasina@fao.org; Tel.: +255 686 132 852

Running head: Early and massive COVID-19 testing saves lives

Summary

To optimize epidemiologic interventions, predictors of mortality should be identified. The US COVID-19 epidemic data –reported up to 3-31-2020– were analyzed using kernel regularized least squares regression. Six potential predictors of mortality were investigated: (i) the number of diagnostic tests performed in testing week I; (ii) the proportion of all tests conducted during week I of testing; (iii) the cumulative number of (test-positive) cases through 3-31-2020, (iv) the number of tests performed/million citizens; (v) the cumulative number of citizens tested; and (vi) the apparent prevalence rate, defined as the number of cases/million citizens. Two metrics estimated mortality: the number of deaths and the number of deaths/million citizens. While both expressions of mortality were predicted by the case count and the apparent prevalence rate, the number of deaths/million citizens was ≈ 3.5 times better predicted by the apparent prevalence rate than the number of cases. In eighteen states, early testing/million citizens/population density was inversely associated with the cumulative mortality reported by 31 March, 2020. Findings support the hypothesis that early and massive testing saves lives. Other factors –e.g., population density– may also influence outcomes. To optimize national and local policies, the creation and dissemination of high-resolution geo-referenced, epidemic data is recommended.

Bullet points

- A multidimensional –numerical, geographic, demographic and temporal– approach that emphasizes interactions is used to identify predictors of COVID-19 related mortality.
- A combinatorial template helps detect the impact of early testing on mortality.
- This rapidly conducted, policy-oriented analysis applies to many geographic scales.

To control a pandemic associated with a substantial mortality –such as COVID-19–, WHO recommends massive testing [1]. In spite of its relevance, the power of testing-related variables to predict mortality has not yet been empirically investigated in this disease.

To predict and identify when and where mortality is likely to occur, at least three types of metrics may be considered, which focus on: (i) cases (counts), (ii) disease prevalence in a specific geographic location and/or time, and (iii) the demographic density of infected locations [2]. However, assessing the actual prevalence of a disease characterized by a substantial number of asymptomatic infections –such as COVID-19– is not possible, unless 100% of the population is tested with a highly sensitive test, repeatedly [3, 4]. Consequently, we use the term *apparent prevalence* to describe the ratio of test-positive cases to all tested individuals. If expressed per million residents, the apparent prevalence can compare different geographical units, e.g., each and all states of the US.

Unfortunately, to conduct comprehensive studies that investigate numerous states, a protracted research program is required. To rapidly provide policy-makers with usable information, here a quasi-real time assessment was designed, which captures both nationwide and state-specific dimensions. Analyzing the epidemic data reported in all 50 states of the USA, during March of 2020 (the month when testing started), we investigated whether testing-related variables –including massive and early testing– predict mortality.

Six variables were assessed as possible predictors of fatalities: (i) the number of diagnostic tests performed in week I of testing; (ii) the proportion of all tests conducted during the first week of testing; (iii) the cumulative number of (test-positive) cases through 3-31-2020, (iv) the number of tests performed/million citizens; (v) the cumulative number of citizens tested; and (vi) the apparent prevalence rate, defined as the number of cases/million citizens. To

examine the predictive ability of these variables, we modeled the data using a nonparametric machine learning approach known as kernel regularized least squares (KRLS) regression [5]. To implement the procedure we used the KRLS *R* software package [6]. KRLS is appropriate when linear regression assumptions –such as linearity and additivity– are not met and the precise functional association between the predictors and criterion is unknown.

Because there is no prior knowledge on the use of these composite variables, no pre-established method or criterion was chosen to analyze the data. Instead, recognition of patterns observed after the data were collected was adopted. When distinct patterns were observed –such as L-shaped data distributions [9]–, thresholds were selected to match the upper limit of a data segment linearly distributed so that the intersection of two orthogonal lines would identify three groups of data.

A public source was used to collect the overall US and state-specific data on the COVID-19 pandemic, which was complemented with state-specific population data [7, 8]. All analyses included data from each state of the US (Supplemental Table 1).

The six predictors accounted for 93.5% of the variance in number of deaths and 86.7% of the variance in deaths/million cases (Supplemental Tables 2A, 2B). Of the six predictors, two were statistically significant: cumulative number of confirmed cases and apparent prevalence rate. These two variables were comparable predictors of mortality count. However, for predicting deaths per million citizens, the apparent prevalence rate was a 3.5 times stronger predictor than was the number of confirmed cases (Supplemental Table 2B).

In addition, the number of tests administered during week one of testing/million citizens/population density distinguished three groups of states when the number of deaths/million citizens was the outcome variable (Fig. 1A). Two of these groups exhibited

statistically significantly different medians ($p < 0.001$, Mann-Whitney test, Fig. **1B**).

Whether cases or fatalities are considered, findings indicate that reporting COVID-19 data as counts is not as informative as reporting metrics that consider two or more interacting quantities, such as the apparent prevalence rate and the number of deaths/million citizens. While isolated metrics –e.g., counts– ignore dynamics as well as geographical factors (including population density), composite metrics integrate numerous dimensions that facilitate geographically-specific interventions [3].

Although the KRLS regression method is a powerful and flexible approach to modeling predictive associations, to rapidly generate results, here it was used to only provide a snapshot-like assessment. If shorter time intervals were used, the KRLS approach could capture epidemic dynamics.

As evidenced by our nonparametric regression results, the variables analyzed offer a combinatorial template that highlights the importance of investigating metrics consisting of interacting quantities. For example, a recombination of those variables (the number of tests performed in week I/million citizens/population density) empirically demonstrate that massive and early testing may save lives (Figs. **1A** and **B**). Such a finding is likely to also be influenced by several factors, including, but not limited to (i) availability of diagnostic kits, equipment, reagents, and trained personnel, (ii) availability of hospital beds and/or Intensive Care Units, and (iii) local and regional demographic and geographical interactions. For example, regions with a higher population density (more abundant and closer contacts among infected and susceptible citizens) tend to be associated with a higher connectivity (more highways, ports and/or airports), which foster epidemic spread [3].

While composite metrics could address pandemics as a group of local and regional

interacting processes, the COVID-19 related information currently found in the press as well as national and international governmental agencies tends to lack point-based (high-resolution), geo-referenced information. While surface-based data are usually provided (e.g., state--related data), this type of data is an aggregate of geographical points and lines and, consequently, internal processes –those affecting specific cities or neighborhoods– are missed [10]. To better identify when and where interventions are most effective, point- (city- or neighborhood-related) and line-based (road-related) data are needed. To optimize these approaches and reduce the COVID-19 related mortality, the collection and reporting of high-resolution, geo-temporal data constructed as interactions is recommended.

Acknowledgements

The authors appreciate the data gathering efforts of those citizens who contributed to Covid-19 tracking (<https://covidtracking.com>) and the comments provided by Dr. Ravi Durvasula (Loyola University Medical School-Chicago).

Financial support

This research received no specific grant from any funding agency, commercial or not-for-profit sectors.

Conflict of Interest

None.

Author contributions

JBH and ALR designed the study. ALH, RP, PK, SDS and FOF extracted the data and reviewed the literature. JBH conducted the statistical analyses. All authors contributed to writing of the report.

References

1. World Health Organization (https://www.who.int/blueprint/priority-diseases/key-action/Global_Research_Forum_FINAL_VERSION_for_web_14_feb_2020.pdf?ua=1 , accessed April 4, 2020).
2. Rivas AL, *et al.* Connecting network properties of rapidly disseminating epizoonotics. *PLoS ONE* 2012; **7**:e39778. doi:10.1371/journal.pone.0039778
3. Nishiura H, Linton NM, Akhmetzhanov AR Serial interval of novel coronavirus (COVID-19) infections. *Int J Inf Dis* 2020; **93**: 284–286. doi:10.1016/j.ijid.2020.02.060
4. Klompas M. Coronavirus disease 2019 (COVID-19): protecting hospitals from the invisible. *Ann Intern Med* [published online, 11 March 2020]. doi:10.7326/M20-0751.
5. Hainmueller J, Hazlett C. Kernel Regularized Least Squares: reducing misspecification bias with a flexible and interpretable machine learning approach. *Political Analysis* 2014; **22**:143–168. doi:10.1093/pan/mpt019
6. R project (<https://www.r-project.org/>)
7. Covidtracking (<https://covidtracking.com/>, accessed April 1, 2020)
8. World Population Review (<https://worldpopulationreview.com/states>, accessed April 1, 2020)
9. Bradley JV. The insidious L-shaped distribution. *Psychon Bull Rev* 1982; **20**: 85–88

- 161 10. Ortiz-Pelaez A *et al.*. Use of social network analysis to characterize the pattern of animal
162 movements in the initial phases of the 2001 foot and mouth disease (FMD) epidemic in the
163 UK. *Prev Vet Med* 2006; **76**: 40–55. doi:10.1016/j.prevetmed.2006.04.007
164

Figure legend

Recognition of COVID-19 mortality-related patterns across the United States. Even a small number of variables, such as the ones reported in Supplemental Table 1, provide a combinatorial template that can reveal additional relationships. For example, when the number of tests performed in the first week of testing (adjusted to state-specific population, expressed per million citizens, and also adjusted to state-specific population density) was plotted against the number of deaths per million citizens reported throughout March of 2020, two perpendicular data segments were observed and the upper limit of each data segment was used as a threshold, that is, the intersection of two perpendicular lines differentiated three groups of states (vertical and horizontal lines, **A**): (i) eleven states that conducted a low number of tests in week I and reported a high number of deaths, (ii) seven states that displayed the opposite pattern, and (iii) the remaining states (**A**). The medians of the variables analyzed differed ≥ 16 times between the group of states characterized by conducting many tests and reporting few deaths and the group of states that exhibited the opposite pattern ($p < 0.001$, inserts, **B**).

181

Supplemental Files

182 **Table 1. Epidemic data collected in all states of the US in March, 2020.**

183

State	<i>Tests wk I</i>	<i>Total tests</i>	<i>Wk I/ all tests</i>	<i>Pop (mill)</i>	<i>Pop dens</i>	<i>Tested/ mill</i>	<i>Cases</i>	<i>Cases/ mill inh</i>	<i>Deaths (count)</i>	<i>Deaths/ mill</i>
New York	1661	172360	0.96	19.440	137.5	8866.2	59513	3061.37	965	49.63
New Jersey	284	35602	0.79	8.936	395.5	3984.1	13386	1497.99	161	18.01
California	4260	90657	4.69	39.937	94.2	2270.0	5708	142.93	123	3.07
Washington	4415	59206	7.45	7.797	42.2	7593.4	4310	552.78	189	24.24
Michigan	274	17379	1.57	10.045	40.1	1730.1	5486	546.14	132	13.14
Florida	1380	48998	2.81	21.992	129.1	2228.0	4950	225.08	59	2.68
Illinois	1622	27762	5.84	12.659	84.4	2193.1	4596	363.06	66	5.21
Massachusetts	171	39066	0.43	6.976	255.2	5600.1	4955	710.29	48	6.88
Louisiana	368	27871	1.32	4.645	34.2	6000.2	3540	762.11	151	32.50
Georgia	48	12596	0.38	3.991	25.9	3156.1	2683	672.26	80	20.04
Pennsylvania	403	33455	1.20	12.820	107.4	2609.6	3394	264.74	38	2.96
Colorado	938	14470	6.48	5.845	21.7	2475.6	2307	394.70	47	8.04
Texas	48	25760	0.18	29.472	42.4	874.0	2552	86.59	34	1.15
Connecticut	551	11900	4.63	3.563	248.2	3339.9	1993	559.36	34	9.54
Tennessee	73	20574	0.35	6.897	63.2	2983.0	1537	222.85	7	1.01
Ohio	148	20665	0.71	11.747	101.2	1759.2	1653	140.72	29	2.46
Wisconsin	259	17662	1.46	5.851	34.5	3018.6	1112	190.05	13	2.22
N. Carolina	17	19072	0.08	10.611	76.1	1797.3	1167	109.98	5	0.47
Indiana	149	9830	1.51	6.745	71.5	1457.4	1514	224.46	32	4.74
Arizona	373	13872	2.68	7.378	25.0	1880.2	919	124.56	17	2.30
S. Carolina	97	3789	2.56	5.210	62.8	727.3	774	148.56	16	3.07
Oklahoma	206	1634	12.60	3.954	21.8	413.2	429	108.50	16	4.04
N Hampshire	232	5396	4.29	1.371	56.6	3935.8	258	188.18	3	2.18
N Mexico	488	11179	4.36	2.096	5.9	5333.5	237	113.07	2	0.95
Delaware	129	3701	3.48	0.982	152.3	3768.8	236	240.33	6	6.11

184

185

186 **Table 1. Epidemic data collected in all states of the US in March, 2020 (cont'd)**

State	<i>Tests wk I</i>	<i>Total tests</i>	<i>Wk I/ all tests</i>	<i>Pop (mill)</i>	<i>Pop dens</i>	<i>Tested/ mill</i>	<i>Cases</i>	<i>Cases/ mill inh</i>	<i>Deaths (count)</i>	<i>Deaths / mill</i>
Maryland	447	13593	3.28	6.083	189.3	2234.6	1239	203.68	10	1.64
Nevada	262	10534	2.48	3.139	10.9	3355.8	920	293.08	15	4.77
Missouri	236	14107	1.67	6.169	34.2	2286.7	903	146.37	12	1.94
Virginia	314	10609	2.95	8.626	77.9	1229.9	890	103.17	22	2.55
Alabama	352	5014	7.02	4.908	36.1	1021.6	830	169.11	4	0.81
Mississippi	969	3318	29.20	2.989	23.8	1110.1	758	253.59	14	4.68
Utah	279	13993	1.99	3.282	14.9	4263.6	719	219.07	2	0.60
Oregon	1023	11426	8.95	4.301	16.9	2656.6	548	127.41	13	3.02
Minnesota	889	17657	5.03	5.700	25.3	3097.7	503	88.24	9	1.57
Kentucky	207	6018	3.43	4.499	43.0	1337.6	439	97.57	9	2.00
Arkansas	115	3453	3.33	3.038	22.1	1136.6	426	140.22	6	1.97
Iowa	330	5349	6.16	3.179	21.8	1682.6	336	105.69	4	1.25
Kansas	167	4513	3.70	2.910	13.7	1550.9	319	109.62	6	2.06
Idaho	427	4706	9.07	1.826	8.4	2577.2	310	169.77	6	3.28
R. Island	550	3134	17.54	1.056	263.9	2967.8	294	278.40	3	2.84
Maine	272	3647	7.45	1.345	14.7	2711.5	253	188.10	3	2.23
Vermont	291	3701	7.86	0.628	25.2	5893.3	235	374.20	12	19.10
Hawaii	12	8013	0.14	1.412	49.9	5674.9	175	123.93	0	0
Montana	160	4069	3.93	1.086	2.8	3746.8	161	148.25	1	0.92
W. Virginia	38	3108	1.22	1.778	28.3	1748.0	124	69.74	0	0
Nebraska	272	2345	11.59	1.952	8.9	1201.3	120	61.47	2	1.02

Alaska	227	3654	6.21	0.734	0.4	4978.2	114	155.31	3	4.08
N. Dakota	393	3724	10.55	0.761	4.2	4893.6	98	128.77	1	1.31
S. Dakota	185	3218	5.74	0.903	4.5	3563.7	90	99.66	1	1.10
Wyoming	308	1641	18.76	0.567	2.2	2894.2	87	153.43	0	0

Predictors

1. *Tests wk I*: number of tests performed in the first 7 days of testing.
2. *Total tested*: total number of people tested.
3. *Wk I / all tests*: tests wk I / total tested, i.e., the proportion of all tests that were conducted during the first week of testing, expressed as a percentage.
4. *Pop (mill)*: the population of each state, expressed in million inhabitants.
5. *Pop dens*: state population density (inhabitants per sq km).
5. *Tested/mill*: number of tests performed per 1 million inhabitants.
6. *Cases*: cumulative number of confirmed (test-positive) infections (through 3-31-2020).
7. *Cases / mill inh*: the apparent prevalence, calculated by dividing the number of cases by the population (expressed in million inhabitants).

Outcomes (cumulative values through 3-31-2020)

1. *Mortality count*: number of deaths (raw count).
2. *Deaths / mill*: number of deaths per 1 million citizens.

Table 2. KRLS regression of potential predictors of COVID-19 related mortality

A – Predictors of the mortality count

Predictors	Estimate	Standard error	<i>t</i> value	Pr (> <i>t</i>) (<i>p</i> -value)
<i>Tests wk I</i>	0.009	0.010	0.926	0.36
<i>Total tested</i>	0.0002	0.003	0.650	0.52
<i>Wk I / all tests (%)</i>	-104.35	118.8	-0.878	0.38
<i>Tested/mill</i>	-0.004	0.003	-1.153	0.25
<i>Cases</i>	0.002	0.0007	3.430	<0.01
<i>Cases/mill inh</i>	69104	21607.2	3.198	<0.01

Estimates are sample-average partial derivatives. Predictors accounted for 93.5% of the variance in mortality count (R^2 : 0.9347)

B – Predictors of deaths per million citizens

Predictors	Estimate	Standard error	<i>t</i> value	Pr (> <i>t</i>) (<i>p</i> -value)
<i>Tests wk I</i>	0.00061	0.0009	0.611	0.54
<i>Total tested</i>	<-0.0001	<0.0001	-1.314	0.19
<i>Wk I / all tests (%)</i>	1.99	11.1	0.179	0.86
<i>Tested/mill</i>	0.0002	0.0003	0.773	0.44
<i>Cases</i>	0.0001	<0.0001	2.214	0.03
<i>Cases/ mill inh</i>	15623.3	2017.1	7.746	<0.0001

Estimates are sample-average partial derivatives. Predictors accounted for 86.7% of the variance in deaths per million citizens (R^2 : 0.8675).